Why the study?
Cardiac troponin-immunoglobulin G (macro-Tn) complexes can interfere with hs-cTn assay function, but the impact of macro-Tn measurements on hs-cTn performance within ESC guideline observe criteria was unknown.
Does adding a single 0h macro-troponin (TnI-IgG) measurement improve the specificity of ruling out acute myocardial infarction and reduce the proportion of patients in the ESC guideline 'observe' pathway in patients presenting to the emergency department with chest pain?
Observational (n=2,955)
Does adding a single 0h macro-troponin (TnI-IgG) measurement improve the specificity of ruling out acute myocardial infarction and reduce the proportion of patients in the ESC guideline 'observe' pathway in patients presenting to the emergency department with chest pain?
Answers are grounded in this paper and cite their sources.
Measuring IgG-bound cardiac troponin (macro-Tn) at presentation enhances ESC guideline 'observe-zone' risk stratification by safely ruling out MI in 10-14% more chest pain patients and significantly improving specificity for both hs-cTnI and hs-cTnT assays.
Background A sizeable proportion of patients presenting to hospital emergency departments (ED) with suspected acute myocardial infarction (MI) have high-sensitivity cardiac troponin (hs-cTn) concentrations that do not meet European Society of Cardiology (ESC) guideline criteria for the 'rule-in' or 'rule-out' pathways and are assigned to the 'observe' pathway. From an analytical perspective, cardiac troponin–immunoglobulin G (macro-Tn) complexes can interfere with hs-cTn assay function, thus leading to erroneous positive or negative results. However, the impact of macro-Tn measurements upon hs-cTn performance within ESC guideline observe criteria is unknown. Methods We measured macro-Tn (TnI-IgG, novel ELISA), hs-cTnI (Abbott ARCHITECT), and hs-cTnT (Roche Gen 5) in EDTA plasma collected at ED presentation (t=0) and 2 hours later (t=2) in n=2,955 patients undergoing investigation for chest pain or suspected MI from 3 previously published studies. Statistical analyses assessed the impact of macro-Tn measurement on the proportion of patients classified in the “observe zone”. Binary logistic regression, ROC AUC, and pathway analyses were used to evaluate macro-Tn effect on low-, medium-, and high-risk categories incorporating both clinical, ECG and log transformed hs-cTn variables. Results Overall, there were 475 patients (22% male, median (IQR) age 71y (59-80), median (IQR) time from symptom to ED presentation 4.5h(2-11)) categorized as “observe” based on 0h hs-TnI values. This observe cohort was decreased by 10–14% (n=43–67) at 0 and 2 hours by adding a single 0h TnI-IgG cutoff of ≥2.5U for rule out for MI, while maintaining a sensitivity of 95–100%. At 100% sensitivity, specificity improved from 12% to 21% (p=0.009). Similar results were observed using 0h hs-cTnT “observe” cases (n=985; 25% male, median age 71y (59-80), median symptom to presentation of 5h (3-11)), where a single 0h TnI-IgG measurement ≥2.5U increased specificity from 7% to 15% with 99% sensitivity (p=0.020). Conclusion Measurement of macro-Tn in patients presenting with chest pain may enhance ESC guideline “observe-zone” risk stratification as a “rule-out” tool. Importantly, this applies to both hs-cTnI and hs-cTnT assays. These findings suggest that macro-Tn measurement may have previously unrecognized clinical utility beyond its potential to confound hs-cTn measurement itself.
No takes yet. Share an insight, caveat, or question.
Wise et al. (2026) conducted an observational in Chest pain or suspected acute myocardial infarction (n=2,955). Macro-troponin (TnI-IgG) measurement (cutoff ≥2.5U at 0h) added to hs-cTn vs. Standard ESC guideline 0h/2h hs-cTnI and hs-cTnT observe-zone criteria alone was evaluated on Specificity for MI rule-out in the hs-cTnI 'observe' cohort at 100% sensitivity (p=0.009).
Synapse has enriched 10 related papers. Consider them for comparative context: